Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nexstim

8.74 EUR0.00 %4.11, 17.29
5,685 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Short Selling
Investor views
Compare
0.00 %
-7.02 %
-7.12 %
-0.34 %
-38.45 %
-39.93 %
+248.21 %
+74.10 %
-98.56 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
70.99M EUR
Turnover
22.27K EUR
P/E (adj.) (26e)
106.8
EV/EBIT (adj.) (26e)
52.94
P/B (26e)
7.15
EV/S (26e)
4.96
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
11.00 EUR
Updated
16.08.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 17.08.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
3rd party
ShowingAll content types

Forum discussions
Near the end there, Mikko had a bit of trouble holding back his smile. ”In 2026, We’re looking at at having a better year in both net sales wise and profitability. So that’s our outlook right now. An we’ve never been at the early October having such a large order backlog right now...
10/29/2026, 9:17 AM
by Kyhnykeisari
28
In Oulu, an easy treatment was discovered that could prevent memory disorders: “With good luck, a Nokia-scale thing” In Finland, a brain buzzer or washing machine is being developed to remove plaque. Tremble, Sinaptica!
yesterday
by Let's make some chimi change!
17
I personally listened with great interest to Mikko when he started talking about EEG. Nexstim clearly believes the TMS+EEG combo is the future and a competitive advantage when tightly integrated with each other. My personal guess is still that Nexstim and Bittium are discussing a...
10/29/2026, 12:27 PM
by AccionHombre
17
Yeah! This is definitely a positive thing and, in fact, a completely expected situation. The economic useful life of Nexstim’s devices is about 7 years, and after that, when a device breaks down, it makes more sense to purchase a new one, as spare parts may no longer be available...
10/29/2026, 7:57 AM
by Kyhnykeisari
15
Right now, things are very much being viewed through negative-tinted glasses, and regarding the deal in this latest press release, the rationale for why acquiring a new device was necessary has been highlighted. That is, the old device is unreliable and even after repairs, the uncertainty...
10/29/2026, 7:43 AM
by Tojopa
14
Great to see this kind of development happening in Finland. It’s quite a bit behind compared to Sinaptica, and these are mutually complementary forms of treatment anyway (one is based on electrical stimulation of neural pathways and the other on physical vibration). First, you shake...
yesterday
11
Personally, I am under the impression that the selling prices for the new-generation devices are higher than before. Support for my claim comes, for example, from this H1/2026 earnings webinar held on August 14, 2026: nexstim.wistia.com Nexstim IR-webinaari 2026 Tervetuloa Nexstimin...
10 hours ago
by Kyhnykeisari
10
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25.2
2027

Annual report '26

Press release04.11.2026, 14.00

Nexstim Plc appoints Ville Saarainen as new CTO

Nexstim
Press release29.10.2026, 08.00

Nexstim Receives Order for NBS 6 System from Finnish Hospital

Nexstim
Regulatory press release27.10.2026, 09.00

Nexstim Plc: Share subscriptions based on stock options 2020 and 2023

Nexstim

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Nexstim Q3'26: System deliveries point to a growth year
Analyst Comment26.10.2026, 10.40
by Antti Siltanen

Nexstim Q3'26: System deliveries point to a growth year

On volume, system sales are clearly ahead of the comparison period.

Nexstim
Press release23.10.2026, 08.00

Nexstim Plc Business Update Q3 2026

Nexstim
Press release14.10.2026, 08.00

Nexstim and Brainlab Advance Neuroscience Capabilities in Portugal with Installation at Hospital da Luz Lisboa

Nexstim
Third party research09.10.2026, 09.37

Nexstim: Conference feedback: Brainlab is set to scale NBS systems - NuWays AG Research

Paris MidCap conference feedback: Brainlab has the strategic fit and the installed base, to significantly scale Nexstim's NBS systems. Estimates unchanged. We remain with BUY and a PT of € 12.

Nexstim
Regulatory press release02.10.2026, 13.00

Nexstim Plc: Managers’ Transactions, Laine

Nexstim
Press release04.09.2026, 08.00

European University Hospital Orders Nexstim NBS 6 System

Nexstim
Press release03.09.2026, 08.00

Nordic Private Clinic Expands Use with Additional NBS 6 System

Nexstim
Third party research02.09.2026, 08.11

Nexstim: Stimulating growth with surgical accuracy; INITIATE with BUY - NuWays AG Research

Nexstim is a Finnish MedTech company and a global leader in navigated transcranial magneticstimulation (nTMS) technology. With nTMS, Nexstim helps (i) surgeons preserve patients' motor and speech cortices and (ii) clinicians treat neurological and psychiatric...

Nexstim
Press release02.09.2026, 08.00

US University Customer Purchases Nexstim NBS 6 for Research Purposes

Nexstim
Press release01.09.2026, 08.00

European Hospital Orders Nexstim NBS 6 System

Nexstim
Press release21.08.2026, 08.00

Nexstim Receives NBS 6 System Order for a European hospital and existing Nexstim customer

Nexstim
Regulatory press release20.08.2026, 12.00

Nexstim Plc: Managers’ Transactions, Weckroth

Nexstim
Press release19.08.2026, 08.00

Nexstim Receives NBS 6 Therapy System Order from New US Customer

Nexstim
Nexstim H1'26: Brainlab potential to be weighed later this year
Research17.08.2026, 09.09
by Antti Siltanen

Nexstim H1'26: Brainlab potential to be weighed later this year

Concrete evidence of the Brainlab collaboration's potential will be available during the rest of the year.

Nexstim
Regulatory press release14.08.2026, 08.00

NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2026 (UNAUDITED)

Nexstim
Press release11.08.2026, 08.00

Notice of Nexstim Plc’s Half-Year Report H1 2026

Nexstim
Nexstim H1'26 preview: Our expectations for the beginning of the year are moderate
Analyst Comment11.08.2026, 08.25
by Antti Siltanen

Nexstim H1'26 preview: Our expectations for the beginning of the year are moderate

We expect the dip in recurring revenue to have weighed on earnings.

Nexstim